• Conners' Teacher Rating Scale-Revised (CTRS-R) [ Time Frame: Measured at study entry and at each week of the drug trial ] [ Designated as safety issue: No ]
• Continuous Performance Test (CPT) [ Time Frame: Measured at study entry and at each week of the drug trial ] [ Designated as safety issue: No ]
• Matching Familiar Figures Test (MFFT) [ Time Frame: Measured at study entry and at each week of the drug trial ] [ Designated as safety issue: No ]
• Speeded Classification Task (SCT) [ Time Frame: Measured at study entry and at each week of the drug trial ] [ Designated as safety issue: No ]
• Delay of Gratification Task (DOG) [ Time Frame: Measured at study entry and at each week of the drug trial ] [ Designated as safety issue: No ]

• 1. Conners’ Teacher Rating Scale-Revised will be completed at study entry and at each week of the drug trial by the child's teacher as the primary measure of MPH response.
• b. Matching Familiar Figures Test
• c. Speeded Classification Task
• d. Delay of Gratification Task
• 2. Several cognitive measures will be used as primary measures of the child's cognitive response to MPH. These will be completed at study entry and at each week of the drug trial by the child and will include:
• a. Continuous Performance Task

• Conners' Parent Rating Scale (CPRS)-Short Form [ Time Frame: Measured at study entry and at each week of the drug trial ] [ Designated as safety issue: No ]
• Side Effects Questionnaire-Parent Version [ Time Frame: Measured at study entry and at each week of the drug trial ] [ Designated as safety issue: Yes ]
• Aberrant Behavior Checklist [ Time Frame: Measured at study entry and at each week of the drug trial ] [ Designated as safety issue: No ]
• ADDH Comprehensive Teacher Rating Scale [ Time Frame: Measured at study entry and at each week of the drug trial ] [ Designated as safety issue: No ]
• Side Effects Questionnaire-Teacher Version [ Time Frame: Measured at study entry and at each week of the drug trial ] [ Designated as safety issue: Yes ]
• Clinician ratings on the Clinical Global Impressions Scale [ Time Frame: Measured at study entry and at each week of the drug trial ] [ Designated as safety issue: No ]
• Selective Listening Tasks (pediatric speech intelligibility and dichotic listening tasks) [ Time Frame: Measured at study entry and at each week of the drug trial ] [ Designated as safety issue: No ]
• Stop Signal Test [ Time Frame: Measured at study entry and at each week of the drug trial ] [ Designated as safety issue: No ]

• 1. Parent rating measures will be completed at study entry and at each week of the drug trial by the child's parent as secondary measures of behavioral response to MPH, and will include:
• a. Conners' Parent Rating Scale-Short Form
• b. Side Effects Questionnaire
• c. Aberrant Behavior Checklist
• 2.Teacher rating measures will be completed at study entry and at each week of the drug trial by the child's teacher as secondary measures of behavioral response to MPH, and will include:
• a. ADD-H Comprehensive Teacher Rating Scale
• 3. Clinician ratings on the Clinical Global Impressions Scale will be completed at study entry and at each week of the drug trial by the study physician as a secondary measure of behavioral response to MPH.
• 4. Other cognitive tasks (completed at study entry and each week of the MPH trial) will be completed as secondary measures of the child's cognitive response to MPH, including:
• a. Selective Listening Task
• b. Children's Embedded Figures Test
• c. Stop Signal Test

This study will first examine the cognitive and behavioral differences in children who have an autism spectrum disorder (ASD) and who do and do not have additional symptoms of attention deficit hyperactivity disorder (ADHD). The study will then examine the effectiveness of a range of doses of methylphenidate in improving cognitive and behavioral outcomes in children with both ASD and ADHD.

Attention Deficit Hyperactivity Disorder (ADHD) is a major comorbid psychiatric disorder in children with Autism Spectrum Disorders (ASD) that significantly undermines behavioral, social, and emotional adjustment. Although the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) does not specifically allow for a comorbid diagnosis of ADHD with ASD, many children with an ASD manifest symptoms of ADHD and are treated for it with stimulants or other medication. The few studies on ADHD in ASD have not consistently established its cognitive and behavioral manifestations, or the optimal parameters for treatment. The proposed project will address these issues through studies of cognitive and behavioral functioning in children with ASD, with and without ADHD, and through a study of medication treatment of ADHD symptoms in autism.

Two groups of participants between the ages of 7 to 12 will participate in the initial phase of the study to examine the differences in children who have an Autism Spectrum Disorder with or without additional symptoms of ADHD. In one group, participants will qualify for a diagnosis of an Autism Spectrum Disorder (Autistic Disorder, Asperger's Disorder, and Pervasive Developmental Disorder-Not Otherwise Specified) and will also have symptoms of ADHD (ASD/ADHD), while in the second group, participants will have an Autism Spectrum Disorder, without symptoms of ADHD (ASD/non-ADHD group). All participants will undergo an initial psychological testing session that includes standardized measures of intellectual, adaptive behavior, language, behavioral, and emotional functioning, along with standardized diagnostic measures to confirm their diagnoses of ASD and/or ADHD (Visit 1). Children with intelligence quotients (IQs) below 50 or greater than 130 or with major sensory, motor, neurological, genetic, or psychiatric disorders that may interfere with testing will be excluded. The participants who meet eligibility criteria will complete computerized tasks of attentional functioning in a second visit (Visit 2).

A subset of the children from the ASD/ADHD group (N=24) will be invited to participate in a six-week randomized double-blind, placebo-controlled treatment trial using various doses (low, medium, or high dose) of methylphenidate (MPH). Children who are invited to participate in the treatment trial will be those who qualified based on the initial phase and who do not have any physical contraindications to MPH (e.g., history of MPH intolerance). In each week of the treatment trial, the child will take one of the three doses of MPH or a placebo. At the end of each week the child will be brought into the clinic by the parent for a medical check-up, parent interviews about the child's behavior and functioning that week, and computerized cognitive testing. Additionally, the child's parent and teacher will be asked to complete questionnaires about the child's behavior each week, so that the child's home and school behaviors at each MPH dose can be assessed.

• Autism
• Attention Deficit Disorder With Hyperactivity

• Drug: Methylphenidate-extended release
• Drug: Methylphenidate-instant release
• Other: Placebo

• No Intervention: Participants with autism and symptoms of ADHD who will undergo the initial psychological testing phase and will be compared to the autism-only group for behavioral, cognitive, and emotional differences
• No Intervention: Participants with autism and do not have symptoms of ADHD who will undergo the initial psychological testing phase and will be compared to the autism-ADHD group for behavioral, cognitive, and emotional differences
• Placebo Comparator: Participants with ASD-ADHD who will undergo 2 weeks of placebo in the MPH treatment phase
• Active Comparator: Participants with ASD-ADHD who will undergo 1 week at a low dose of MPH in the MPH treatment phase
• Active Comparator: Participants with ASD-ADHD who will undergo 1 week at a medium dose of MPH in the MPH treatment phase
• Active Comparator: Participants with ASD-ADHD who will undergo 1 week at a high dose of MPH in the MPH treatment phase

Inclusion Criteria:

Autism/ADHD Group:

• DSM-IV diagnosis of autistic disorder, as per the Autism Diagnostic Interview-Revised (ADI-R) and the Autism Diagnostic Observation Schedule (ADOS)
• Child manifests current symptoms of ADHD

Autism/non-ADHD Group:

• Meets the diagnostic criteria for autism, as above, but does not meet the diagnostic criteria for ADHD

Exclusion Criteria:

In both groups, exclusion criteria will include:

• Sensory or motor deficits sufficient to interfere with testing (e.g., blindness, severe cerebral palsy)
• Serious neurological disorders (e.g., epilepsy, stroke)
• Down syndrome, fragile X syndrome, Tourette syndrome, or fetal alcohol syndrome
• Bipolar disorder or a family history of bipolar disorder in a first-degree relative
• Other serious psychopathology that resulted in psychiatric hospitalization (e.g., for psychotic episode). The investigators will screen for this using the Diagnostic Interview for Children and Adolescents (DICA)-IV, and getting a complete developmental/medical history
• Serious physical handicaps that would interfere with performance on laboratory tasks
• IQ less than 50 and greater than 130
• Verbal mental age (VMA) less than 36 months (to exclude participants unable to understand simple task instructions)

In the autism/ADHD group, further exclusion criteria apply to the MPH trial:

• History of intolerance to MPH
• Weight less than 20 kg or greater than 59 kg (less than 44 pounds or greater than 130 pounds)
• Concomitant use of dextroamphetamine preparations (Dexedrine, Dextrostat), mixed amphetamine salts (Adderall XR), other MPH preparations (e.g., Concerta, Metadate); venlafaxine, bupropion, atomoxetine, guanfacine, modafinil.
• Concomitant use of any herbal preparations
• Medical condition for which stimulants are contraindicated (e.g., high blood pressure)
• Past treatment failure on a methylphenidate trial